

# Muhammad Usman Rashid

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6073005/publications.pdf>

Version: 2024-02-01

45  
papers

2,303  
citations

331670

21  
h-index

276875

41  
g-index

47  
all docs

47  
docs citations

47  
times ranked

4666  
citing authors

#	ARTICLE	IF	CITATIONS
1	Cancer Risks Associated With <i>BRCA1</i> and <i>BRCA2</i> Pathogenic Variants. <i>Journal of Clinical Oncology</i> , 2022, 40, 1529-1541.	1.6	90
2	Chasing the origin of 23 recurrent <i>BRCA1</i> mutations in Pakistani breast and ovarian cancer patients. <i>International Journal of Cancer</i> , 2022, , .	5.1	4
3	SARS-COV-2 infection and lung tumor microenvironment. <i>Molecular Biology Reports</i> , 2021, 48, 1925-1934.	2.3	22
4	Clinical Characteristics of COVID-19-Infected Cancer Patients in Pakistan: Differences Between Survivors and Non-Survivors. <i>Frontiers in Oncology</i> , 2021, 11, 655634.	2.8	4
5	In-Silico Analyses of Nonsynonymous Variants in the <i>BRCA1</i> Gene. <i>Biochemical Genetics</i> , 2021, 59, 1506-1526.	1.7	7
6	Epidemiological Assessment of Oral Cancer Burden in Pakistan. <i>Cancer Investigation</i> , 2021, 39, 842-853.	1.3	5
7	Association of Genomic Domains in <i>BRCA1</i> and <i>BRCA2</i> with Prostate Cancer Risk and Aggressiveness. <i>Cancer Research</i> , 2020, 80, 624-638.	0.9	39
8	Absence of the <i>TRIP13</i> c.1060C>T Mutation in Wilms Tumor Patients From Pakistan. <i>Journal of Pediatric Hematology/Oncology</i> , 2020, 42, e128-e131.	0.6	0
9	Characterization of the Cancer Spectrum in Men With Germline <i>BRCA1</i> and <i>BRCA2</i> Pathogenic Variants. <i>JAMA Oncology</i> , 2020, 6, 1218.	7.1	48
10	Transcriptome-wide association study of breast cancer risk by estrogen receptor status. <i>Genetic Epidemiology</i> , 2020, 44, 442-468.	1.3	32
11	Prevalence of <i>RECQL</i> germline variants in Pakistani early-onset and familial breast cancer patients. <i>Hereditary Cancer in Clinical Practice</i> , 2020, 18, 25.	1.5	6
12	Forkhead box P3 and indoleamine 2,3-dioxygenase co-expression in Pakistani triple negative breast cancer patients. <i>World Journal of Clinical Oncology</i> , 2020, 11, 1018-1028.	2.3	2
13	Prevalence and spectrum of <i>MLH1</i> , <i>MSH2</i> , and <i>MSH6</i> pathogenic germline variants in Pakistani colorectal cancer patients. <i>Hereditary Cancer in Clinical Practice</i> , 2019, 17, 29.	1.5	9
14	Spectrum and prevalence of <i>BRCA1/2</i> germline mutations in Pakistani breast cancer patients: results from a large comprehensive study. <i>Hereditary Cancer in Clinical Practice</i> , 2019, 17, 27.	1.5	24
15	Association between Cyclooxygenase-2 and Indoleamine 2,3-Dioxygenase Expression in Breast Cancer Patients from Pakistan. <i>Asian Pacific Journal of Cancer Prevention</i> , 2019, 20, 3521-3525.	1.2	4
16	Prevalence of <i>PALB2</i> Germline Mutations in Early-onset and Familial Breast/Ovarian Cancer Patients from Pakistan. <i>Cancer Research and Treatment</i> , 2019, 51, 992-1000.	3.0	9
17	Mutational spectrum in a worldwide study of 29,700 families with <i>BRCA1</i> or <i>BRCA2</i> mutations. <i>Human Mutation</i> , 2018, 39, 593-620.	2.5	224
18	INHERITED GENETIC SUSCEPTIBILITY TO BREAST CANCER IN PAKISTAN. <i>Journal of Cancer &amp; Allied Specialties</i> , 2018, 4, .	0.3	1

#	ARTICLE	IF	CITATIONS
19	<i>BRCA2</i> Hypomorphic Missense Variants Confer Moderate Risks of Breast Cancer. <i>Cancer Research</i> , 2017, 77, 2789-2799.	0.9	75
20	Contribution of BRCA1 large genomic rearrangements to early-onset and familial breast/ovarian cancer in Pakistan. <i>Breast Cancer Research and Treatment</i> , 2017, 161, 191-201.	2.5	13
21	Nanomedicine and cancer immunotherapy: focus on indoleamine 2,3-dioxygenase inhibitors. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 463-476.	2.0	17
22	Indoleamine 2,3-dioxygenase: As a potential prognostic marker and immunotherapeutic target for hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2017, 23, 2286.	3.3	23
23	HOW TO WRITE A SCIENTIFIC RESEARCH PAPER. <i>Journal of Cancer &amp; Allied Specialties</i> , 2017, 3, .	0.3	0
24	Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. <i>Breast Cancer Research</i> , 2016, 18, 64.	5.0	31
25	High prevalence and predominance of BRCA1 germline mutations in Pakistani triple-negative breast cancer patients. <i>BMC Cancer</i> , 2016, 16, 673.	2.6	26
26	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. <i>Nature Communications</i> , 2016, 7, 12675.	12.8	78
27	Current Status of the Management of Hereditary Breast and Ovarian Cancer in Asia: First Report by the Asian BRCA Consortium. <i>Public Health Genomics</i> , 2016, 19, 53-60.	1.0	42
28	Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. <i>Nature Genetics</i> , 2016, 48, 374-386.	21.4	125
29	<i>BRCA1</i> genetic testing in a Pakistani breast-ovarian cancer family with multiple consanguineous marriages. <i>Clinical Genetics</i> , 2015, 88, 198-199.	2.0	1
30	Absence of the FANCM c.5101C>T mutation in BRCA1/2-negative triple-negative breast cancer patients from Pakistan. <i>Breast Cancer Research and Treatment</i> , 2015, 152, 229-230.	2.5	7
31	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. <i>Nature Genetics</i> , 2015, 47, 164-171.	21.4	221
32	Association of Type and Location of <i>BRCA1</i> and <i>BRCA2</i> Mutations With Risk of Breast and Ovarian Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1347.	7.4	390
33	Association between the BsmI Polymorphism in the Vitamin D Receptor Gene and Breast Cancer Risk: Results from a Pakistani Case-Control Study. <i>PLoS ONE</i> , 2015, 10, e0141562.	2.5	37
34	Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia. <i>Breast Cancer Research</i> , 2014, 16, 3419.	5.0	97
35	Deleterious RAD51C germline mutations rarely predispose to breast and ovarian cancer in Pakistan. <i>Breast Cancer Research and Treatment</i> , 2014, 145, 775-784.	2.5	28
36	Prevalence of TP53 germ line mutations in young Pakistani breast cancer patients. <i>Familial Cancer</i> , 2012, 11, 307-311.	1.9	19

#	ARTICLE	IF	CITATIONS
37	Identification of the deleterious 2080insA BRCA1 mutation in a male renal cell carcinoma patient from a family with multiple cancer diagnoses from Pakistan. <i>Familial Cancer</i> , 2011, 10, 709-712.	1.9	7
38	Interplay between BRCA1 and RHAMM Regulates Epithelial Apicobasal Polarization and May Influence Risk of Breast Cancer. <i>PLoS Biology</i> , 2011, 9, e1001199.	5.6	91
39	No association of miscarriage and BRCA carrier status in Pakistani breast/ovarian cancer patients with a history of parental consanguinity. <i>Breast Cancer Research and Treatment</i> , 2009, 116, 211-213.	2.5	3
40	Absence of the BRCA1 del (exons 9&#x2013;12) mutation in breast/ovarian cancer families outside of Mexican Hispanics. <i>Breast Cancer Research and Treatment</i> , 2009, 117, 679-681.	2.5	19
41	High proportion of BRCA1/2 founder mutations in Hispanic breast/ovarian cancer families from Colombia. <i>Breast Cancer Research and Treatment</i> , 2007, 103, 225-232.	2.5	86
42	No association between BRCA mutations and sex ratio in offspring of Pakistani BRCA mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2007, 107, 155-156.	2.5	1
43	Commonly Studied Single-Nucleotide Polymorphisms and Breast Cancer: Results From the Breast Cancer Association Consortium. <i>Journal of the National Cancer Institute</i> , 2006, 98, 1382-1396.	6.3	238
44	Prevalence of BRCA1 and BRCA2 mutations in Pakistani breast and ovarian cancer patients. <i>International Journal of Cancer</i> , 2006, 119, 2832-2839.	5.1	98
45	Prevalence of FANCM germline variants in BRCA1/2 negative breast and/or ovarian cancer patients from Pakistan. <i>Familial Cancer</i> , 0, , .	1.9	0